Condition
Recurrent Bladder Carcinoma
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 7 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
7 shownCollecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial CancerNCT01050504 · 2009-08-01
RECRUITINGTrigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or LymphomaNCT03229278 · 2017-10-03
COMPLETEDsEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney CancerNCT02767921 · 2016-08-02
TERMINATEDNanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR MutationsNCT02646319 · 2016-01-01
COMPLETEDTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)NCT02465060 · 2015-08-17
ACTIVE_NOT_RECRUITINGRomidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver DysfunctionNCT01638533 · 2012-08-03
COMPLETEDVaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid TumorsNCT01522820 · 2012-03-01
COMPLETEDCommon interventions
Laboratory Biomarker AnalysisOTHER6Cytology Specimen Collection ProcedureOTHER3NivolumabBIOLOGICAL2Pharmacological StudyOTHER2AdavosertibDRUG1AfatinibDRUG1Afatinib DimaleateDRUG1BinimetinibDRUG1Biopsy ProcedurePROCEDURE1Biospecimen CollectionPROCEDURE1CapivasertibDRUG1Computed TomographyPROCEDURE1CopanlisibDRUG1Copanlisib HydrochlorideDRUG1CrizotinibDRUG1DabrafenibDRUG1Dabrafenib MesylateDRUG1DasatinibDRUG1DEC-205/NY-ESO-1 Fusion Protein CDX-1401BIOLOGICAL1DefactinibDRUG1Defactinib HydrochlorideDRUG1Echocardiography TestPROCEDURE1Enzyme Inhibitor TherapyDRUG1ErdafitinibDRUG1FexagratinibDRUG1
Mapped drugs appearing in these trials
Shared trial participation only; not evidence of efficacy or approval.
Leading sponsors
Trial status mix
COMPLETED4
ACTIVE_NOT_RECRUITING1
RECRUITING1
TERMINATED1
Phase mix
PHASE14
EARLY_PHASE11
PHASE21
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.